Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)---- $INCY #ASCO21--Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Incyte and MorphoSys Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Up 1.2% Since Last Earnings Report: Can It Continue?

Eli Lilly

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) will present data from post-hoc analyses that suggested OLUMIANT® (baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to HUMIRA® (adalimumab) and placebo. These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

OLUMIANT® Improved Pain, Physical Function and Morning Joint Stiffness in Rheumatoid Arthritis in Phase 3 Post-Hoc Analyses

Incyte has seen some product approvals in 2020, starting to make an initial dent to drive diversification going forward. I like the potential of the company over the long haul, as diversification efforts are still in the early innings.

Incyte: Slowly Moving Along

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Positive Analysis from Phase 2 OPTIC Study of Ponatinib (Iclusig) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at ASCO 2021

Positive Primary Analysis from the Phase 2 OPTIC Study of Ponatinib (Iclusig®) in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) to be Presented at the 2021 ASCO Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO21--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.

Incyte (INCY) Announces Positive Results From Vitiligo Study

Incyte Corporation (NASDAQ: INCY) has announced positive topline results from its pivotal Phase 3 TRuE-V trial program evaluating ruxolitinib cream in adolescent and adult patients (age ≥12 years) with vitiligo, a skin condition defined by the loss of pigment cells. Phase 3 trials of ruxolitinib cream have met their primary endpoints.

Incyte's Ruxolitinib Cream Aces Late-Stage Vitiligo Trials, Teeing Up Regulatory Submissions

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo.

Incyte Announces Positive Results from Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EHA2021--Data from Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

Data From Incyte's Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

PLANEGG, Germany & MUNICH & WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for DLBCL

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

Morphosys AG - ADR

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as first-line treatment for high-intermediate and high-risk patients with untreated diffuse large B-cell lymphoma (DLBCL). Tafasitamab is a humanized, monoclonal antibody designed to effectively target the B-cell specific antigen CD19 and to induce immune cell activation.

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

CAMBRIDGE, England--(BUSINESS WIRE)--Crescendo Biologics Ltd (Crescendo), a clinical-stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces the appointment of Dr Michael Booth as Chief Financial Officer (CFO). Mike joins with over 20 years' experience in corporate finance within the biopharmaceutical industry. Mike joins Crescendo at an important stage of its development, following the initiation of its Phase Ia/Ib trial for Crescendo's lead Huma

Crescendo Biologics Further Strengthens Leadership Team With Appointment of Dr Michael Booth as Chief Financial Officer

Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.

Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi

Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q1 2021 Results - Earnings Call Transcript

Incyte Corporation (NASDAQ: INCY) reported Q1 earnings of $0.67, better than the consensus of $0.64, but sales of $604.7 million fell short of expectations of $659.2 million. Overall product and royalty revenues increased 6% Y/Y stemming from a 1% increase in Jakafi's (ruxolitinib) net product revenues of $465.7 million, the launch of Pemazyre, and higher product royalty revenues from Jakavi and Olumiant.

Incyte's Q1 Jakafi Sales Hit By Pandemic; Reaffirms 2021 Guidance

Incyte (INCY) delivered earnings and revenue surprises of 3.08% and -7.77%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Tops Q1 Earnings Estimates

Shares of Incyte (NASDAQ:INCY) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share increased 123.43% year over year to $0.67, which beat the estimate of $0.64.

Recap: Incyte Q1 Earnings

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte (INCY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Incyte (INCY) This Earnings Season?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #SID2021--Incyte Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology Virtual Meeting 2021

Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.

Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?

Incyte Corporation (NASDAQ: INCY) has announced findings from three pooled analyses of its Phase 3 studies, TRuE-AD1 and TRuE-AD2 evaluating ruxolitinib cream to treat atopic dermatitis (AD). Data presented at the American Academy of Dermatology Virtual Meeting Experience 2021 showed Ruxolitinib demonstrated greater improvement in all analyzed efficacy endpoints than vehicle.

Incyte Announces New Ruxolitinib Data From Atopic Dermatitis and Vitiligo Studies

INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through new analyses of BREEZE-AD5 Phase 3 clinical trial data and an extended safety analysis across multiple trials, Eli Lilly and Company (NYSE: LLY) and Incyte's (NASDAQ:INCY) OLUMIANT® (baricitinib) 2-mg tablet taken once daily showed improvement in key measured treatment outcomes compared to placebo, and helped further characterize the long-term safety profile in adults with moderate to severe atopic dermatitis (AD). In one BREEZE-AD5 analysis, OLUMIANT provided concurrent improvements in the severity and extent of AD, other key symptoms and quality of life as early as one week, as measured by percent change from baseline compared to placebo.

OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AADVMX2021--Incyte Announces New Findings from Pooled Analyses of the Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients with Atopic Dermatitis

News for Incyte Stock (INCY)